MannKind Corporation (MNKD)
NASDAQ: MNKD · IEX Real-Time Price · USD
5.71
-0.01 (-0.17%)
At close: Jul 19, 2024, 4:00 PM
5.79
+0.08 (1.40%)
Pre-market: Jul 22, 2024, 7:14 AM EDT
MannKind Revenue
MannKind had revenue of $224.60M in the twelve months ending March 31, 2024, with 74.92% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $66.26M with 63.10% year-over-year growth. In the year 2023, MannKind had annual revenue of $198.96M with 99.42% growth.
Revenue (ttm)
$224.60M
Revenue Growth
+74.92%
P/S Ratio
6.92
Revenue / Employee
$542,510
Employees
414
Market Cap
1.55B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
Dec 31, 2018 | 27.86M | 16.11M | 137.20% |
Dec 31, 2017 | 11.75M | -163.01M | -93.28% |
Dec 31, 2016 | 174.76M | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 35.00K | -15.00K | -30.00% |
Dec 31, 2011 | 50.00K | -43.00K | -46.24% |
Dec 31, 2010 | 93.00K | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 20.00K | 10.00K | 100.00% |
Dec 31, 2007 | 10.00K | -90.00K | -90.00% |
Dec 31, 2006 | 100.00K | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Dec 31, 2001 | 326.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.62B |
Supernus Pharmaceuticals | 597.40M |
Alphatec Holdings | 511.63M |
Kiniksa Pharmaceuticals | 301.77M |
Schrödinger | 188.48M |
Avadel Pharmaceuticals | 55.14M |
MNKD News
- 4 weeks ago - INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions - GlobeNewsWire
- 6 weeks ago - Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions - GlobeNewsWire
- 7 weeks ago - Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - PRNewsWire
- 7 weeks ago - MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix - GlobeNewsWire
- 2 months ago - MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update - GlobeNewsWire
- 2 months ago - MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease - GlobeNewsWire
- 2 months ago - MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024 - GlobeNewsWire
- 2 months ago - MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases - GlobeNewsWire